Bristol-Myers Squibb Co

lastchangevolume
25.7265 +0.0765 (+0.30%) 3.33M

About

flag this description
Bristol-Myers Squibb (NYSE: BMY), often referred to as BMS, is a pharmaceutical company, headquarted in New York City. The company was formed in 1989, following the merger its predecessors Bristol-Myers and the Squibb Corporation. Squibb was founded in 1858 by Edward Robinson Squibb in Brooklyn, New York, while Bristol-Myers was founded in 1887 by William McLaren Bristol and John Ripley Myers in Clinton, New York (both were graduates of Hamilton College). James M. Cornelius is the company's Chairman and CEO and was granted $25.0 million in compensation in 2008 according to Forbes. Bristol-Myers Squibb manufactures prescription pharmaceuticals in several therapeutic areas, including cancer, HIV/AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis and psychiatric disorders. It is also the parent company of Mead Johnson Nutrition, which manufactures nutritional products such as Enfamil baby formulas and infant vitamin supplements like Tri-Vi-Sol. Bristol-Myers Squibb has a mission to "Extend and Enhance Human Life" and works to discover and develop medicines in areas of serious unmet medical need.
Full description of Bristol-Myers Squibb at Freebase
Freebase CC-BY
Source: Freebase, licensed under CC-BY
Other content from Wikipedia, licensed under the GFDL

A Bristol-Myers Squibb research campus in Princeton, New Jersey

A Bristol-Myers Squibb research campus in Princeton, New Jersey
Source: Freebase, licensed under CC-BY

Bms

Bms
Source: Bristol-myers squibb

Market Capitalization44.099B
52w Range18.83 - 26.62
1yr Target25.60
Dividend (Yield)1.25 (4.87)
Average Volume (3m)21,243,400

5-Day Activity Chart

Bristol-Myers Sq Intraday Chart

Updated Mar 11 11:43am ET
One of the objectives of the SAVOR-TIMI 53 study is to test superiority of treatment with ONGLYZA versus placebo when added to current therapy, as well as exclude unacceptable cardiovascular risk
Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus
Through this investment in India we are able to focus on one of the largest areas at risk from LF and support the Indian Government’s current efforts to control and eliminate this crippling tropical disease.
This acquisition will further strengthen Abbott's biologics capabilities and pharmaceutical pipeline

Timeline

Top Articles on Timeline

Disclaimer: All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Not liable for informational errors. Prices delayed atleast 15 minutes.